Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Cancer Res. 2013 May 10;73(11):3316–3325. doi: 10.1158/0008-5472.CAN-12-3015

Figure 2.

Figure 2

Effect of LD22-4 on malignant glioma tumors in a mouse orthotopic model. CD-1 nu/nu female mice were implanted with 1 × 105 U87MG tumor cells expressing luciferase. One week later, 20μl of saline containing 0 (●), 0.44 μg (▲), or 4.4 μg (■) LD22-4 was infused at the site of the tumor. Treatment was repeated every four days and tumor size was measured every 7 days by BLI (arrows). Treatment with LD22-4 was terminated at day 23 and the animals sacrificed at day 35. A. Tumor response to LD22-4. Mean BLI values ± S.D. at each time point. B. Scatter plot of BLI values at day 35. C. Repeat of the experiment presented in A with 4.4 μg LD22-4. D. Histological evaluation of tumors after treatment with 4.4 μg LD22-4. Control animals, left panel; treated animals, right panel. The location of tumor cell implantation is circled. Magnification, 4X.